Equities

Harrow Inc

HROW:NMQ

Harrow Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)49.91
  • Today's Change-2.11 / -4.06%
  • Shares traded799.00
  • 1 Year change+289.16%
  • Beta0.7436
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

  • Revenue in USD (TTM)154.15m
  • Net income in USD-33.58m
  • Incorporated2006
  • Employees315.00
  • Location
    Harrow Inc102 WOODMONT BLVD, SUITE 610NASHVILLE 37215United StatesUSA
  • Phone+1 (615) 733-4731
  • Fax+1 (858) 345-1745
  • Websitehttps://www.harrow.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Collegium Pharmaceutical Inc599.25m88.59m1.01bn197.0015.714.324.271.692.002.0013.057.270.42616.252.923,041,853.006.302.799.384.8062.3650.8814.785.160.88323.940.78730.0022.1715.11292.60---54.77--
Phibro Animal Health Corp1.05bn17.41m1.02bn1.94k58.383.9318.900.96970.42930.429325.826.381.082.606.75539,568.101.803.932.204.9031.4731.181.663.771.692.200.647256.454.074.21-92.59-46.356.650.8548
Avadel Pharmaceuticals PLC (ADR)95.15m-106.22m1.27bn154.00--18.00--13.31-1.17-1.171.040.73060.53080.69415.41617,850.60-59.26-40.21-80.97-47.9994.62---111.64-374.752.52-10.250.00-----22.99-16.59------
Innoviva Inc352.75m64.59m1.27bn112.0029.541.9012.183.610.68790.68794.7810.680.29161.144.443,149,509.005.3426.245.9828.5387.93--18.3176.841.641.930.4011---6.303.53-15.99-14.57----
ANI Pharmaceuticals Inc555.46m-8.77m1.28bn642.00--3.1724.862.31-0.4489-0.448928.6720.440.51021.752.96865,196.30-0.6514-2.83-0.7654-3.3559.7960.18-1.28-6.151.970.70180.5921--53.8719.28131.250.17549.08--
Tilray Brands Inc812.04m-212.62m1.33bn2.65k--0.37--1.64-0.2746-0.27461.033.970.18752.318.73306,429.10-4.64---5.15--29.42---24.78--1.57-1.160.0953--25.80--83.14------
Ocular Therapeutix Inc61.10m-138.36m1.65bn267.00--4.37--27.05-1.09-1.090.52492.430.1912.362.12228,827.70-43.26-46.70-47.93-54.1890.8489.36-226.46-228.6516.55-11.300.1509--13.4996.60-13.65--26.37--
Immunocore Holdings PLC - ADR281.45m-53.44m1.69bn497.00--4.70--6.00-1.07-1.075.557.180.35560.56795.56566,303.60-6.75-27.55-8.35-36.8299.41---18.99-97.125.15--0.5495--43.0551.23-5.22--2.85--
Harrow Inc154.15m-33.58m1.77bn315.00--30.25--11.49-0.9508-0.95084.381.650.5814.954.39489,352.40-12.66-10.86-14.77-12.7171.1670.75-21.78-15.352.43-0.35180.7608--46.9525.77-73.30--143.88--
Tarsus Pharmaceuticals Inc83.37m-150.07m1.81bn244.00--7.17--21.71-4.43-4.432.436.630.2947--5.36341,696.70-53.05-31.56-60.10-33.8292.50---180.00-242.596.99--0.221---32.42---118.86--279.39--
Endo Inc-100.00bn-100.00bn1.93bn3.00k--1.05----------23.99------------------------1.52--0.5697---13.25--15.87------
Harmony Biosciences Holdings Inc681.88m122.63m2.00bn246.0016.603.3513.622.932.112.1111.7510.460.799424.269.172,771,866.0014.387.4617.129.0878.6580.5817.9810.463.20--0.23450.0032.93---28.99---25.31--
Supernus Pharmaceuticals Inc651.97m59.71m2.09bn652.0035.422.0714.613.201.071.0711.7118.240.49620.96894.54999,957.104.544.955.836.4189.0488.619.1612.841.98--0.00---8.958.24-97.83-58.81-8.17--
Ligand Pharmaceuticals Inc133.48m42.14m2.28bn58.0054.272.8229.5217.092.222.227.3342.820.16430.47894.082,301,345.005.1912.325.3512.9991.8281.6531.5780.3215.81--0.00002---33.09-12.181,131.21-17.8642.63--
Amphastar Pharmaceuticals Inc723.55m157.72m2.31bn1.76k15.873.1710.933.193.013.0113.7915.040.46842.835.60410,873.9010.289.4211.8811.5652.9847.8321.9515.232.619.420.45060.0029.1416.9450.51---4.00--
Data as of Nov 12 2024. Currency figures normalised to Harrow Inc's reporting currency: US Dollar USD

Institutional shareholders

37.99%Per cent of shares held by top holders
HolderShares% Held
Opaleye Management, Inc.as of 30 Jun 20243.99m11.25%
Private Capital Management LLCas of 30 Jun 20242.71m7.65%
BlackRock Fund Advisorsas of 30 Jun 20241.97m5.56%
The Vanguard Group, Inc.as of 30 Jun 20241.78m5.01%
Geode Capital Management LLCas of 30 Jun 2024718.77k2.03%
SSgA Funds Management, Inc.as of 30 Jun 2024715.42k2.02%
Stifel Nicolaus & Co., Inc. (Investment Management)as of 30 Jun 2024542.85k1.53%
TIAA-CREF Investment Management LLCas of 30 Jun 2024363.09k1.02%
Royce & Associates LPas of 30 Sep 2024360.32k1.02%
First Turn Management LLCas of 30 Sep 2024326.58k0.92%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.